---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-22-000043"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:33:45.217232+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics reports Q3 2022 net loss of $25.1M; cash runway into H2 2024

## Summary
- Cash, cash equivalents and marketable securities of $215.6M as of Sept 30, 2022, down from $291.1M at Dec 31, 2021.
- Net loss for Q3 2022 was $25.1M, compared to $14.4M in Q3 2021.
- R&D expenses increased to $19.0M (Q3 2022) from $10.5M (Q3 2021); G&A expenses rose to $7.0M from $3.9M.
- On track to file IND for ENTR-601-44 (Duchenne exon 44 skipping) in Q4 2022; second IND for ENTR-701 (DM1) planned for H2 2023.
- Preclinical data for ENTR-701 presented at World Muscle Society; collaboration entered with Myotonic Dystrophy Clinical Research Network.

## SEC filing metadata
- accession: 0001689375-22-000043
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/0001689375-22-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/trda-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-22-000043
- JSON: https://secwatch.observer/filing/0001689375-22-000043.json
- Plain text: https://secwatch.observer/filing/0001689375-22-000043.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $25.1 million.
  - Period: the quarter ended September 30, 2022
  - Net income: Net loss for the third quarter of 2022 was $25.1 million
  - Result: reported results
  source text: Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/0001689375-22-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.